{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059538","form_type":"8-K","ticker":null,"cik":"0001966494","company_name":"CARGO Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.332491+00:00","generated_at":"2026-06-02T01:23:53.329774+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CARGO Therapeutics reports Q1 2024 net loss $35.8M; Phase 2 firi-cel trial on track for 1H25 interim data","bullets":["Q1 2024 net loss of $35.8M ($0.87/share); cash, equivalents and marketable securities $375.9M providing runway into 2026.","Phase 2 FIRCE-1: 26 sites activated, >20 patients dosed; IDMC recommended continuation without modifications; interim results expected 1H25.","Phase 1 Stanford firi-cel data: median OS 25.7 months at DL1; ORR 68%, CR 53% across all patients (n=38) at median follow-up 31.4 months.","Dr. Kapil Dhingra appointed to board of directors in April 2024.","R&D expenses $30.5M (incl. $1.7M stock-based comp); G&A expenses $10.3M (incl. $2.2M stock-based comp)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059538","json":"https://secwatch.observer/filing/0000950170-24-059538.json","markdown":"https://secwatch.observer/filing/0000950170-24-059538.md","text":"https://secwatch.observer/filing/0000950170-24-059538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1966494/000095017024059538/0000950170-24-059538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1966494/000095017024059538/crgx-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:23:53.329774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f71006a11490f68e39ad5d54fdfd06d476b41118","claim":"CARGO Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, CARGO Therapeutics, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1966494/000095017024059538/0000950170-24-059538-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}